Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

doi:10.1093/jjco/hys042

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Japanese journal of clinical oncology - 1 Jun 2012

Takeda Masayuki, Okamoto Isamu, Tsurutani Junji, Oiso Naoki, Kawada Akira, Nakagawa Kazuhiko

Abstract excerpt

OBJECTIVE: Somatic mutations in the epidermal growth factor receptor gene are associated with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors such as gefitinib and erlotinib in patients with non-small cell lung cancer. Although the safety profile of these dru...

Topics

Adult
Aged
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Disease Progression
Disease-Free Survival
ErbB Receptors
Erlotinib Hydrochloride
Female
Gefitinib
Humans
Kaplan-Meier Estimate
Lung Neoplasms
Male
Middle Aged
Mutation
Neoplasm Staging
Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 22457323
DOI: 10.1093/jjco/hys042

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-22457323-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics